The difference in one sentence
Tesamorelin reproduces the full GHRH molecule (44 amino acids); CJC-1295 is built on its active fragment (the first 29). Both are GHRH analogues — same class, different size.
What GHRH is
tesaVsCjc.s2p1
tesaVsCjc.s2p2
| Feature | Tesamorelin | CJC-1295 |
|---|---|---|
| Basis | Full GHRH (44 amino acids) | Active fragment GHRH(1-29) |
| Stabilisation | N-terminal modification | Amino acid substitutions, optional DAC |
| Class | GHRH analogue | GHRH analogue |
Two strategies
Tesamorelin keeps the full length and adds a modification at the N-terminus that protects the molecule against rapid enzymatic breakdown.
CJC-1295 goes the other way: start from the short active fragment and substitute several amino acids to make it more stable. The DAC variant (Drug Affinity Complex) additionally binds albumin, extending circulation time; the non-DAC variant does not.
Why a blend with ipamorelin is something else
Ipamorelin is not a GHRH analogue but a GHRP: it acts through the ghrelin receptor, a different point of action. A blend of CJC-1295 and ipamorelin therefore combines two distinct mechanisms in one vial. That is why the combination is offered as its own product rather than a variant of either.
What this article does not cover
No statements about efficacy, dosing, side effects or which is superior. Every product named is supplied strictly for laboratory research.
Further
See Tesamorelin · CJC-1295 + Ipamorelin · reconstitutie
For in-vitro laboratory research only. Not for human consumption. Not medical advice.
Last updated: August 2026